In the US, Gemtuzumab (gemtuzumab systemic) is a member of the drug class CD33 monoclonal antibodies and is used to treat Acute Myeloid Leukemia.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Therapeutic Categories


Cytostatic agent

Chemical Name

Immunoglobulin G4 (human-mouse monoclonal hP67.6 gamma 4-chain anti-human antigen CD 33), disulfide with human-mouse monoclonal hP67.6 gamma-chain, dimer (WHO)

Foreign Names

  • Gemtuzumabum (Latin)
  • Gemtuzumab (German)
  • Gemtuzumab (French)
  • Gemtuzumab (Spanish)

Generic Names

  • Gemtuzumab Ozogamicin (OS: USAN)
  • CDP 771 (IS: WyethAyerst)
  • CMA 676 (IS: WyethAyerst)
  • Gemtuzumab zogamicin (IS)
  • hP67.6-calicheamicin (IS)
  • WAY-CMA 676 (IS: WyethAyerst)

Brand Names

  • Mylotarg
    Wyeth, Argentina; Wyeth, Israel; Wyeth, United States; Wyeth, Venezuela; Wyeth KK, Japan

International Drug Name Search


ISInofficial Synonym
OSOfficial Synonym
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Click for further information on drug naming conventions and International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.